Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evonik buys into low-cost peptides

by Alex Scott
September 25, 2017 | A version of this story appeared in Volume 95, Issue 38

Evonik Industries has acquired a minority stake in Numaferm, a spin-off from Heinrich Heine University that is developing a process for making peptides using bacteria. Evonik is one of a handful of companies, including venture capital firms, that have invested a combined total of about $1.2 million in the spin-off. Numaferm claims it can make peptides at 1/1,000th of the price of standard chemical process costs (about $1.2 million per kg). Numaferm’s technology is cheaper partly because to make 1 kg of peptide, it uses 1 metric ton of raw materials compared with 25 metric tons for chemical processes, the firm says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.